{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T15:44:16Z","timestamp":1778341456133,"version":"3.51.4"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2023IR16"],"award-info":[{"award-number":["2023IR16"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022CR81"],"award-info":[{"award-number":["2022CR81"]}]},{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling"},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["24QZ003"],"award-info":[{"award-number":["24QZ003"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82090023"],"award-info":[{"award-number":["82090023"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82330019"],"award-info":[{"award-number":["82330019"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100784"],"award-info":[{"award-number":["82100784"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370709"],"award-info":[{"award-number":["82370709"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"publisher","award":["2022A1515110162"],"award-info":[{"award-number":["2022A1515110162"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Planning Project of Guangzhou","award":["202201010955"],"award-info":[{"award-number":["202201010955"]}]},{"DOI":"10.13039\/100017415","name":"Peking University First Hospital","doi-asserted-by":"publisher","award":["2022CR81"],"award-info":[{"award-number":["2022CR81"]}],"id":[{"id":"10.13039\/100017415","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Leukemia inhibitory factor (LIF) has been implicated in the production of galactose-deficient immunoglobulin A1 (IgA1) and development of renal fibrosis, and has emerged in several genome-wide association studies as a hotspot gene of IgA nephropathy (IgAN). Therefore, we hypothesize that urinary LIF (uLIF) could predict the renal prognosis and\/or treatment response to immunosuppressive therapy in IgAN patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prognostic study was conducted in a retrospective cohort of 506 biopsy-confirmed IgAN patients. Baseline uLIF concentrations were measured using enzyme-linked immunosorbent assay. Kidney disease progression was defined as a 40% decline in estimated glomerular filtration rate (eGFR), progression to end-stage kidney disease or death due to kidney disease. Additionally, a subcohort derived from the Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) trial was used to investigate the association between changes in uLIF and the response to methylprednisolone therapy in IgAN patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over a median of 35 months of follow-up, 16.6% participants of the prognostic cohort reached the composite kidney progression event. After adjusting for sex, age, eGFR, proteinuria and systolic blood pressure, elevated levels of uLIF\/urinary creatinine (uLIF\/Cr) were independently associated with an increased risk of kidney progression [per natural log (uLIF\/Cr) increment: hazard ratio (HR) 2.16; 1.13\u20134.13; P for trend 0.019]. In TESTING subcohort, the methylprednisolone group showed a significant greater reduction in uLIF\/Cr than the placebo group (41.9% vs 25.4% at 6th month, P\u00a0=\u00a0.039; 59.2% vs 19.8% at 12th month, P\u00a0&amp;lt;\u00a0.001). The LIF decline group exhibited a significant lower risk of kidney progression compared with LIF non-decline group (adjusted HR 0.431; 0.255\u20130.730; P for trend 0.002).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides strong initial evidence that uLIF\/Cr levels are linked to renal prognosis in IgAN. Moreover, reductions in uLIF\/Cr may indicate improved outcomes in patients receiving methylprednisolone. Collectively, our findings suggest uLIF\/Cr levels may serve as a valuable biomarker for predicting both renal prognosis and treatment response in IgAN patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfaf164","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T11:38:01Z","timestamp":1755949081000},"page":"138-148","source":"Crossref","is-referenced-by-count":1,"title":["Association of urinary LIF levels with disease prognosis and treatment response to methylprednisolone in IgA nephropathy"],"prefix":"10.1093","volume":"41","author":[{"given":"Lei","family":"Zhang","sequence":"first","affiliation":[{"name":"Southern Medical University State Key Laboratory of Multi-organ Injury Prevention and Treatment, National Clinical Research Center of Kidney Disease, Department of Nephrology, Nanfang Hospital, , Guangzhou ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaping","family":"Dong","sequence":"additional","affiliation":[{"name":"Peking University First Hospital; Institute of Nephrology, Peking University; Key Laboratory of Renal Disease, Ministry of Health of China; Key Laboratory of CKD Prevention and Treatment (Peking University), Ministry of Education of China; Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences Renal Division, Department of Medicine, , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liling","family":"Xie","sequence":"additional","affiliation":[{"name":"Southern Medical University State Key Laboratory of Multi-organ Injury Prevention and Treatment, National Clinical Research Center of Kidney Disease, Department of Nephrology, Nanfang Hospital, , Guangzhou ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Southern Medical University State Key Laboratory of Multi-organ Injury Prevention and Treatment, National Clinical Research Center of Kidney Disease, Department of Nephrology, Nanfang Hospital, , Guangzhou ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Xu","sequence":"additional","affiliation":[{"name":"Peking University First Hospital; Institute of Nephrology, Peking University; Key Laboratory of Renal Disease, Ministry of Health of China; Key Laboratory of CKD Prevention and Treatment (Peking University), Ministry of Education of China; Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences Renal Division, Department of Medicine, , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Chao","sequence":"additional","affiliation":[{"name":"Peking University First Hospital; State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University Health Science Center, Peking University Biobank of Peking University First Hospital, Department of Clinical Medical Research, , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yacong","family":"An","sequence":"additional","affiliation":[{"name":"Peking University First Hospital; State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University Health Science Center, Peking University Biobank of Peking University First Hospital, Department of Clinical Medical Research, , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University First Hospital; Institute of Nephrology, Peking University; Key Laboratory of Renal Disease, Ministry of Health of China; Key Laboratory of CKD Prevention and Treatment (Peking University), Ministry of Education of China; Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences Renal Division, Department of Medicine, , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jicheng","family":"Lv","sequence":"additional","affiliation":[{"name":"Peking University First Hospital; Institute of Nephrology, Peking University; Key Laboratory of Renal Disease, Ministry of Health of China; Key Laboratory of CKD Prevention and Treatment (Peking University), Ministry of Education of China; Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences Renal Division, Department of Medicine, , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xujie","family":"Zhou","sequence":"additional","affiliation":[{"name":"Peking University First Hospital; Institute of Nephrology, Peking University; Key Laboratory of Renal Disease, Ministry of Health of China; Key Laboratory of CKD Prevention and Treatment (Peking University), Ministry of Education of China; Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences Renal Division, Department of Medicine, , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Nie","sequence":"additional","affiliation":[{"name":"Peking University First Hospital; State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University Health Science Center, Peking University Biobank of Peking University First Hospital, Department of Clinical Medical Research, , Beijing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"2025122223465285200_bib1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N Engl J Med"},{"key":"2025122223465285200_bib2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","article-title":"Epidemiology of IgA nephropathy: a global perspective","volume":"38","author":"Schena","year":"2018","journal-title":"Semin Nephrol"},{"key":"2025122223465285200_bib3","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.molmed.2015.10.003","article-title":"Molecular insights into the pathogenesis of IgA nephropathy","volume":"21","author":"Robert","year":"2015","journal-title":"Trends Mol Med"},{"key":"2025122223465285200_bib4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025122223465285200_bib5","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","article-title":"Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population","volume":"27","author":"Le","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2025122223465285200_bib6","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2025122223465285200_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment","volume":"21","author":"Cheung","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"2025122223465285200_bib8","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"2025122223465285200_bib9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int"},{"key":"2025122223465285200_bib10","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"2025122223465285200_bib11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"2025122223465285200_bib12","doi-asserted-by":"publisher","first-page":"e2254054","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025122223465285200_bib13","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.7150\/thno.32352","article-title":"Blocking interleukin-6 trans-signaling protects against renal fibrosis by suppressing STAT3 activation","volume":"9","author":"Chen","year":"2019","journal-title":"Theranostics"},{"key":"2025122223465285200_bib14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ekir.2022.12.023","article-title":"Elevated urinary IL-6 predicts the progression of IgA nephropathy","volume":"8","author":"Zhao","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025122223465285200_bib15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ymthe.2022.12.016","article-title":"Leukemia inhibitory factor, a double-edged sword with therapeutic implications in human diseases","volume":"31","author":"Wang","year":"2023","journal-title":"Mol Ther"},{"key":"2025122223465285200_bib16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ekir.2023.11.003","article-title":"LIF\/JAK2\/STAT1 signaling enhances production of galactose-deficient IgA1 by IgA1-producing cell lines derived from tonsils of patients with IgA nephropathy","volume":"9","author":"Yamada","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2025122223465285200_bib17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/ng.787","article-title":"Genome-wide association study identifies susceptibility loci for IgA nephropathy","volume":"43","author":"Gharavi","year":"2011","journal-title":"Nat Genet"},{"key":"2025122223465285200_bib18","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ng.3118","article-title":"Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens","volume":"46","author":"Kiryluk","year":"2014","journal-title":"Nat Genet"},{"key":"2025122223465285200_bib19","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","article-title":"Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy","volume":"55","author":"Kiryluk","year":"2023","journal-title":"Nat Genet"},{"key":"2025122223465285200_bib20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3390\/biomedicines9050457","article-title":"Identification of novel biomarker for early detection of diabetic nephropathy","volume":"9","author":"Kim","year":"2021","journal-title":"Biomedicines"},{"key":"2025122223465285200_bib21","doi-asserted-by":"publisher","first-page":"104312","DOI":"10.1016\/j.ebiom.2022.104312","article-title":"Leukemia inhibitory factor is a therapeutic target for renal interstitial fibrosis","volume":"86","author":"Xu","year":"2022","journal-title":"EBioMedicine"},{"key":"2025122223465285200_bib22","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney Int"},{"key":"2025122223465285200_bib23","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"2025122223465285200_bib24","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1159\/000519812","article-title":"The therapeutic evaluation of steroids in IgA nephropathy global (TESTING) study: trial design and baseline characteristics","volume":"52","author":"Wong","year":"2021","journal-title":"Am J Nephrol"},{"key":"2025122223465285200_bib25","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","article-title":"Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer","volume":"18","author":"Jones","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2025122223465285200_bib26","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/jcm13040947","article-title":"An update on current therapeutic options in IgA nephropathy","volume":"13","author":"Lim","year":"2024","journal-title":"J Clin Med"},{"key":"2025122223465285200_bib27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin a nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"2025122223465285200_bib28","doi-asserted-by":"publisher","first-page":"e2401899121","DOI":"10.1073\/pnas.2401899121","article-title":"Leukemia inhibitory factor (LIF) receptor amplifies pathogenic activation of fibroblasts in lung fibrosis","volume":"121","author":"Nguyen","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025122223465285200_bib29","doi-asserted-by":"publisher","first-page":"10204","DOI":"10.1038\/ncomms10204","article-title":"Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts","volume":"6","author":"Albrengues","year":"2015","journal-title":"Nat Commun"},{"key":"2025122223465285200_bib30","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.cytogfr.2015.07.001","article-title":"Leukemia inhibitory factor (LIF)","volume":"26","author":"Nicola","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"2025122223465285200_bib31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10753-023-01910-6","article-title":"LIF aggravates pulpitis by promoting inflammatory response in macrophages","volume":"47","author":"Guo","year":"2024","journal-title":"Inflammation"},{"key":"2025122223465285200_bib32","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.bbi.2014.11.010","article-title":"Leukemia inhibitory factor tips the immune balance towards regulatory T cells in multiple sclerosis","volume":"45","author":"Janssens","year":"2015","journal-title":"Brain Behav Immun"},{"key":"2025122223465285200_bib33","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1523-1755.2005.00390.x","article-title":"Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy","volume":"68","author":"Xu","year":"2005","journal-title":"Kidney Int"},{"key":"2025122223465285200_bib34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000505748","article-title":"Leukemia inhibitory factor signaling enhances production of galactose-deficient IgA1 in IgA nephropathy","volume":"6","author":"Yamada","year":"2020","journal-title":"Kidney Dis"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf164\/64114418\/gfaf164.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/1\/138\/64114418\/gfaf164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/1\/138\/64114418\/gfaf164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T04:46:57Z","timestamp":1766465217000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/1\/138\/8240258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,23]]},"published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf164","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,8,23]]}}}